Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that many adults with a depressive disorder, Bipolar Disorder (BPD), or an anxiety disorder may also have undiagnosed Attention-Deficit/Hyperactivity Disorder (ADHD), according to a longitudinal retrospective medical claims analysis presented today at a major medical meeting of child and adolescent psychiatrists.
What’s the best treatment for a cold? Some say rest and lots of liquids, others say to feed a cold and starve a fever. But what if a person has a cold with a fever? Does medication help?
Abbott announced results from a study showing HUMIRA? (adalimumab) induced significantly higher rates of clinical remission compared to placebo in patients with moderately to severely active Crohn’s disease who lost response to, or were intolerant to, infliximab therapy. The data is being presented simultaneously at the American College of Gastroenterology (ACG) annual meeting in Las Vegas and the United European Gastroenterology Week (UEGW) in Berlin.
Australian researchers have found that exposure to measured doses of ultraviolet light, such as sunlight, could reduce asthma. The research team at Perth’s Telethon Institute for Child Health Research, through funding provided by the Asthma Foundation of WA, studied the effect of ultraviolet light on the development of asthma-like symptoms in mice, such as inflamed airways and lungs.
A new test could now be able to improve doctors’ ability to recommend the right type of cancer treatment for their patients. According to the researchers, the test, which has been developed by Anil Potti at the Duke Institute for Genome Sciences and Policy in Durham, North Carolina, is 80% accurate in predicting the right chemotherapy to cure each person’s cancer.
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has granted approval of a new 300 mg single capsule formulation of REYATAZ? (atazanavir sulfate) for the treatment of HIV-1 infection in adults as part of combination therapy. Taken once daily along with ritonavir and food as part of a anti-HIV drug regimen, the REYATAZ 300 mg single capsule formulation can replace two REYATAZ 150 mg capsules for: patients who have previously received anti-HIV medicines, patients who will be receiving tenofovir disoproxil fumarate, and patients who have never taken anti-HIV medicines that require SUSTIVA? (efavirenz) as part of their anti-HIV drug regimen. The REYATAZ single capsule formulation will be available in the United States within seven business days.
The Federal Trade Commission (FTC) and the Food and Drug Administration (FDA), working with government agencies in Mexico and Canada, have launched a drive to stop deceptive Internet advertisements and sales of products misrepresented as cures or treatments for diabetes. The ongoing joint campaign has so far included approximately 180 warning letters and other advisories sent to online outlets in the three countries.
Chronic Renal (Kidney) Failure is a fatal disease where bodily waste products (in the form of urine) collected in the body which leads to multiorgan failure. There are three procedures in modern medicine for such condition –
Osteoporosis, a disease characterized by low bone mass that often leads to fractures of the hip, spine and wrist, affects more than 5 million Californians, most of whom are women.(1) In observation of World Osteoporosis Day on October 20, Dairy Council of California offers tips to help women and their families reduce their risk of osteoporosis throughout their lifetimes by eating a healthy diet rich in calcium and other bone-building nutrients, and participating in weight-bearing cardiovascular activities.
Researchers in the Greene Infectious Disease Laboratory at Columbia University’s Mailman School of Public Health, the Centers for Disease Control and Prevention, and the Caribbean Primate Research Center have discovered a key mechanism by which the Filoviruses, Ebola and Marburg, cause disease. The identification of an amino acid sequence in Filoviruses that results in the rapid depression of immunological response is described in the December 2006 issue of The FASEB Journal. Using this information, researchers can begin to develop new drugs to stop these devastating diseases.